SearchDictionaryMobileLogin

Pulmonary Tuberculosis

Subscribe to Selected New Research on Pulmonary Tuberculosis
7950  relevant articles (188 outcomes, 728 trials/studies) found for this Disease

Description: MYCOBACTERIUM infections of the lung.

Also Known As:
Tuberculosis, Pulmonary; Pulmonary Tuberculoses; Tuberculoses, Pulmonary; Phthises, Pulmonary; Phthisis, Pulmonary; Pulmonary Phthises; Pulmonary Phthisis

Relationship Network

Disease Context: Research Results

-
Bacterial Infections and Mycoses
-
Bacterial Infections: 6830
-
Gram-Positive Bacterial Infections: 93
-
Actinomycetales Infections: 1
-
Mycobacterium Infections: 23
-
Tuberculosis: 21000
-
Pulmonary Tuberculosis: 7950
*
Silicotuberculosis: 69
-
Respiratory Tract Diseases: 377
-
Lung Diseases: 8942
-
Pulmonary Tuberculosis: 7950
*
Silicotuberculosis: 69
-
Respiratory Tract Infections: 5595
-
Pulmonary Tuberculosis: 7950
*
Silicotuberculosis: 69

Related Diseases

1. Tuberculosis
2. Infection
3. Meningeal Tuberculosis (Tuberculous Meningitis)
4. Sarcoidosis (Schaumann Disease)
5. Miliary Tuberculosis

Experts

1. Narayanan, P R: 18 articles (09/2008 - 05/2000)
2. Selvaraj, P: 14 articles (09/2008 - 05/2000)
3. Mishin, V Iu: 9 articles (01/2004 - 01/2000)
4. Jawahar, M S: 7 articles (11/2007 - 05/2004)
5. Donald, P R: 6 articles (08/2007 - 12/2000)
6. Johnson, J L: 6 articles (06/2006 - 04/2000)
7. Raja, Alamelu: 5 articles (04/2008 - 07/2003)
8. Sirgel, F A: 5 articles (02/2008 - 12/2000)
9. Koh, Won-Jung: 5 articles (01/2008 - 04/2004)
10. Venter, A: 5 articles (08/2007 - 12/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pulmonary Tuberculosis:
1. Isoniazid (Ftivazide)FDA LinkGeneric
04/01/1996 - "OBJECTIVES: To compare the pharmacokinetic parameters and the clinical efficacy of isoniazid, administered in 10 mg/kg or 5 mg/kg to children suffering from pulmonary tuberculosis. "
11/15/2004 - "In these studies, the EBA of isoniazid during the first 2 days of treatment was determined for 97 patients with sputum smear-positive pulmonary tuberculosis following isoniazid doses of < or =37.5 mg, 75 mg, 150 mg, 300 mg, and 600 mg. The NAT2 genotype was determined in 70 patients, and the association between EBA and genotype was examined in this subgroup. "
01/01/2003 - "A complex approach to the therapy of patients with destructive pulmonary tuberculosis is suggested, within the study, with regard for the presence of multidrug-resistance of Mycobacterium tuberculosis (MBT), for a degree of inactivation of isoniazid and for a degree of bacterial-static activity of patient's blood, which provides for a higher treatment efficiency."
09/01/2001 - "In light of the study findings, and as per the recommendation of the World Health Organization, we suggest that a 4-drug regimen, as an initial treatment for pulmonary tuberculosis should be maintained, as resistance to isoniazid is still higher than the cut off value of 4%, and susceptibility testing for first line antituberculosis drugs should be carried out whenever possible. "
02/01/1977 - "1. The acetylator phenotype of over 600 pulmonary tuberculosis patients treated with intermittent isoniazid-containing regimens in two controlled clinical trials was determined using either sulphadimidine or a slow-release isoniazid formulation. "
Order ALL the reference details at left...
2. Rifampin (Rifampicin)FDA LinkGeneric
3. Streptomycin (Streptomycin Sulfate)FDA Link
4. PyrazinamideFDA LinkGeneric
5. Ethambutol (Myambutol)FDA LinkGeneric
6. Tuberculin (PPD)IBA
7. Anti-Bacterial Agents (Antibiotics)IBA
8. BCG VaccineIBA
9. p-Aminosalicylic Acid (PAS)FDA Link
10. AntigensIBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Immunotherapy
3. Retreatment
4. Pneumonectomy (Lung Volume Reduction)
5. Collapse Therapy

Best Treatments:
Research Summary Report
on Pulmonary Tuberculosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 188 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>